Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil Infusion for Preventing Post-operative Opioid-induced Hyperalgesia
NCT03812003Phase 4Completed
- Sponsor
- Tri-Service General Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of remifentanil in opioid-induced hyperalgesia (OIH) (2 arms), sponsored by Tri-Service General Hospital. Primary endpoints: Numerical Rating Score for pain at 30 minutes and Amount of analgesic requirement at 30 minutes. Started Jan 2019; status: completed.
02
Drugs
remifentanil
03
Conditions
opioid-induced hyperalgesia (OIH)
Beyond the preview
Go deeper on NCT03812003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812003.